• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal.

作者信息

Lubberman Floor J E, van Erp Nielka P, Ter Heine Rob, van Herpen Carla M L

机构信息

a Department of Pharmacy , Radboud University Medical Center , Nijmegen , The Netherlands.

b Department of Medical Oncology , Radboud University Medical Center , Nijmegen , The Netherlands.

出版信息

Acta Oncol. 2017 Sep;56(9):1238-1240. doi: 10.1080/0284186X.2017.1311024. Epub 2017 Apr 7.

DOI:10.1080/0284186X.2017.1311024
PMID:28388255
Abstract
摘要

相似文献

1
Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal.使用CYP3A4抑制剂提高阿昔替尼的血药浓度，实现阿昔替尼治疗的个体化。
Acta Oncol. 2017 Sep;56(9):1238-1240. doi: 10.1080/0284186X.2017.1311024. Epub 2017 Apr 7.
2
Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma.基于阿昔替尼首剂量浓度-时间曲线下面积的转移性肾细胞癌个体化剂量。
Clin Genitourin Cancer. 2019 Feb;17(1):e1-e11. doi: 10.1016/j.clgc.2018.09.015. Epub 2018 Sep 29.
3
Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.抗逆转录病毒增效剂考比司他可增加达比加群在HIV阴性健康志愿者体内的药代动力学暴露量及抗凝效果。
Circulation. 2016 Dec 6;134(23):1909-1911. doi: 10.1161/CIRCULATIONAHA.116.025257.
4
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.依维莫司或阿昔替尼作为晚期肾细胞癌二线靶向治疗的真实世界用药剂量和药物成本：美国一项回顾性图表审查
J Med Econ. 2016;19(5):462-8. doi: 10.3111/13696998.2015.1131705. Epub 2016 Jan 11.
5
Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial.阿昔替尼新辅助治疗局部晚期透明细胞肾细胞癌后肾肿瘤-实质界面的研究：一项II期试验的配对分析
J Urol. 2017 Mar;197(3 Pt 1):559-565. doi: 10.1016/j.juro.2016.09.081. Epub 2016 Sep 25.
6
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.阿昔替尼治疗转移性肾细胞癌：超越二线治疗。
Future Oncol. 2017 Sep;13(21):1839-1852. doi: 10.2217/fon-2017-0104. Epub 2017 Jul 14.
7
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.阿昔替尼对比索拉非尼作为转移性肾细胞癌患者的一线治疗：一项随机开放标签的 3 期临床试验。
Lancet Oncol. 2013 Dec;14(13):1287-94. doi: 10.1016/S1470-2045(13)70465-0. Epub 2013 Oct 25.
8
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.考比司他与利托那韦增效作用的比较及与合并用药药物相互作用特征的差异。
J Antimicrob Chemother. 2016 Jul;71(7):1755-8. doi: 10.1093/jac/dkw032. Epub 2016 Mar 5.
9
Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma.阿昔替尼致蛋白尿与转移性肾细胞癌患者的疗效。
Int J Clin Oncol. 2016 Aug;21(4):748-755. doi: 10.1007/s10147-015-0933-1. Epub 2015 Dec 22.
10
Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma.阿昔替尼治疗复发性肾癌患者时出现的危及生命的高钾血症
Intern Med. 2018 Oct 1;57(19):2895-2900. doi: 10.2169/internalmedicine.0262-17. Epub 2018 May 18.

引用本文的文献

1
Validation of a LC-MS/MS Assay for Rapid and Simultaneous Quantification of Cobicistat and Venetoclax in Human Plasma and Serum.用于快速同时定量人血浆和血清中可比司他和维奈克拉的液相色谱-串联质谱法的验证
Biomed Chromatogr. 2025 Sep;39(9):e70179. doi: 10.1002/bmc.70179.
2
Pharmacokinetic Boosting of Kinase Inhibitors.激酶抑制剂的药代动力学增强
Pharmaceutics. 2023 Apr 5;15(4):1149. doi: 10.3390/pharmaceutics15041149.
3
Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib.
利托那韦增强的激酶抑制剂暴露：一项与厄洛替尼的开放标签、交叉药代动力学概念验证试验。
Pharm Res. 2022 Apr;39(4):669-676. doi: 10.1007/s11095-022-03244-8. Epub 2022 Mar 29.
4
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.通过 CYP3A 抑制来有意调节伊布替尼的药代动力学。
Cancer Res Commun. 2021 Nov;1(2):79-89. doi: 10.1158/2767-9764.crc-21-0076. Epub 2021 Nov 9.
5
Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites.在第三间隙迷失：恶性腹水患者酪氨酸激酶抑制剂药代动力学改变。
Cancer Chemother Pharmacol. 2022 Feb;89(2):271-274. doi: 10.1007/s00280-021-04377-0. Epub 2021 Dec 1.
6
Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients.基于药代动力学的剂量调整以提高布加替尼在非小细胞肺癌患者中的疗效。
Br J Clin Pharmacol. 2022 Feb;88(4):1930-1934. doi: 10.1111/bcp.15088. Epub 2021 Oct 7.
7
Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.通过有意的药物-药物相互作用来提高抗癌药物的口服生物利用度。
Basic Clin Pharmacol Toxicol. 2022 Jan;130 Suppl 1(Suppl 1):23-35. doi: 10.1111/bcpt.13623. Epub 2021 Jun 28.
8
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.使用 CYP3A 抑制剂考比司他提高间变性淋巴瘤激酶阳性非小细胞肺癌患者低克唑替尼血药浓度
Clin Transl Sci. 2021 Mar;14(2):487-491. doi: 10.1111/cts.12921. Epub 2020 Nov 22.
9
Cobicistat: A case of mislabelled drug-drug interaction risk?考比司他：一例药物标签错误导致的药物相互作用风险病例？
Br J Clin Pharmacol. 2020 May;86(5):834-836. doi: 10.1111/bcp.14262. Epub 2020 Mar 6.